HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM: NTEC) today announced that the two abstracts submitted by the Company’s collaborative partner, Novo Nordisk A/S, relating to GlycoPEGylated recombinant Factor VIIa have been accepted for poster presentations at the XXIst Congress of the International Society on Thrombosis and Haemostatis taking place in Geneva, Switzerland from July 6-12, 2007. The abstracts, which were co-authored by Novo Nordisk and Neose, are as follows:
